All In MedTech

Device Trial Radar · NCT05481359

AF-FLOW Registry to Evaluate Electrographic Flow Mapping in Patients Undergoing Ablation for Atrial Fibrillation

A Post Market, Global Registry to Evaluate the Identification of Atrial Fibrillation Sources Using Electrographic Flow (EGF™) Mapping System to Guide Ablation Therapy in Patients With Atrial Fibrillation in Real-world Setting.

Last checked: Nov 20, 2026Latest source record: Apr 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

25

Actual

Start

Sep 12, 2022

Primary completion

Oct 27, 2022

Study completion Nov 17, 2023

Sponsor

Lead sponsor
Ablacon, Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
Cortex
First posted
Aug 1, 2022

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This post-market global registry will evaluate the ability of Electrographic Flow (EGF™) mapping to identify atrial fibrillation (AF) sources and guide ablation therapy in patients with atrial fibrillation in real-world setting.

Conditions

  • Atrial Fibrillation, Persistent
  • Atrial Fibrillation
  • Arrhythmias, Cardiac
  • Heart Diseases

Interventions

  • Electrographic Flow™ (EGF) mapping and ablationDevice

    Electrographic Flow™ (EGF) mapping enables the full spatiotemporal reconstruction of organized atrial electrical wavefront propagation to identify active sources or origins of excitation that may trigger atrial fibrillation (AF). EGF mapping involves 1 minute recordings of unipolar electrograms from a basket catheter, which are then processed with the EGF algorithm (Ablamap® Software). Several basket catheter positions are acquired in standard positions in both the left and right atria. EGF-identified sources with activity levels exceeding the recommended threshold are deemed significant and are targeted for ablation. The success of the ablation is confirmed through an EGF remap, where elimination of the source is defined as reduction of EGF source activity below the threshold.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Acute Procedure SuccessTime frame: During the procedure

Locations

5 sites in 3 countries. Site status is shown where the registry gives one.

  • Piedmont Healthcare

    Athens, Georgia

  • Piedmont Atlanta Hospital

    Atlanta, Georgia

  • Mount Sinai Hospital

    New York, New York

2 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.